Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898472 | 0.80 | HCAR2 (0.49) | CYP2D6HCAR2KMT2ASRCLMNA | |
| SCHEMBL198133 | 0.76 | HCAR2 (0.45) | CYP2D6HCAR2LMNATSHR | |
| SCHEMBL7940900 | 0.76 | CYP2D6 (0.52) | CYP2D6HCAR2KMT2ASRCLMNA | |
| SCHEMBL7940904 | 0.76 | CYP2D6 (0.52) | CYP2D6HCAR2KMT2ASRCLMNA | |
| SCHEMBL6272307 | 0.74 | HCAR2 (0.46) | CYP2D6HCAR2KMT2ASRCLMNA | |
| SCHEMBL360231 | 0.74 | KLK7 (0.54) | CYP2D6KMT2ALMNATP53TSHR | |
| SCHEMBL360232 | 0.74 | KLK7 (0.54) | CYP2D6KMT2ALMNATP53TSHR | |
| Ammonia Solution, Strong SCHEMBL27871924 | 0.74 | HCAR2 (0.44) | CYP2D6HCAR2LMNATSHR | |
| Phosphine SCHEMBL20897413 | 0.74 | CYP2D6 (0.46) | CYP2D6HCAR2LMNATSHR | |
| Hydrochloric Acid SCHEMBL28273439 | 0.74 | ALDH1A1 (0.44) | CYP2D6HCAR2KMT2ALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960420-B2 | Diazonamide analogs with improved solubility | JOYANT PHARMACEUTICALS, INC (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090163446-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | JOYANT PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163446-A1 | DIAZONAMIDE ANALOGS WITH IMPROVED SOLUBILITY | PKD1, PKD2, GLS | CYP2D6 911/4885HCAR2 1563/4885KMT2A 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.